A NON-INTERVENTIONAL OBSERVATIONAL RETROSPECTIVE STUDY OF SECOND-LINE TREATMENT WITH THE COMBINATION DARATUMUMAB - BORTEZOMIB - DEXAMETHASONE (DARAVD) IN MULTIPLE MYELOMA PATIENTS REFRACTORY TO LENALIDOMIDE

被引：0
|
作者：
Rizzello, I. [1 ]
Zamagni, E. [1 ]
Solli, V. [1 ]
Poletti, A. [1 ]
Tacchetti, P. [1 ]
Pantani, L. [1 ]
Mancuso, K. [1 ]
Rocchi, S. [1 ]
De Cicco, G. [1 ]
Fusco, A. [1 ]
Ursi, M. [1 ]
Barbato, S. [1 ]
Terragna, C. [1 ]
Martello, M. [1 ]
Testoni, N. [1 ]
Marzocchi, G. [1 ]
Cavo, M. [1 ]
机构：
[1] Univ Bologna, Dipartimentodi Med Specialist Diagnost & Sperimen, Ist Ematol Seragnoli, IRCCS Azienda Osped, Bologna, Italy
来源：
HAEMATOLOGICA | 2021年 / 106卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
D135
引用
收藏
页码：167 / 168
页数：2
相关论文
共 50 条
  • [21] Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
    Fazio, Francesca
    Franceschini, Luca
    Tomarchio, Valeria
    Rago, Angela
    Garzia, Maria Grazia
    Cupelli, Luca
    Bongarzoni, Velia
    Andriani, Alessandro
    Gumenyuk, Svitlana
    Tafuri, Agostino
    Siniscalchi, Agostina
    Piciocchi, Alfonso
    De Fabritiis, Paolo
    De Rosa, Luca
    di Toritto, Tommaso Caravita
    Annibali, Ombretta
    Cantonetti, Maria
    Petrucci, Maria Teresa
    [J]. EJHAEM, 2022, 3 (01): : 121 - 128
  • [22] Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma
    Dimopoulos, Meletios A.
    Beksac, Meral
    Benboubker, Lotfi
    Roddie, Huw
    Allietta, Nathalie
    Broer, Esther
    Couturier, Catherine
    Mazier, Marie-Andree
    Angermund, Ralf
    Facon, Thierry
    [J]. HAEMATOLOGICA, 2013, 98 (08) : 1264 - 1272
  • [23] DARATUMUMAB COMBINED WITH DEXAMETHASONE AND LENALIDOMIDE OR BORTEZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS: REPORT FROM THE MULTIPLE MYELOMA GIMEMA LAZIO GROUP
    Fazio, F.
    Franceschini, L.
    Tomarchio, V.
    Rago, A.
    Garzia, M. G.
    Cupelli, L.
    Bongarzoni, V.
    Rosati, S.
    Gumenyku, S.
    Antolino, G.
    Siniscalchi, A.
    Proietti, G.
    Piciocchi, A.
    De Fabritiis, P.
    De Rosa, L.
    Caravita, T.
    Annibali, O.
    Cantonetti, M.
    Petrucci, M. T.
    [J]. HAEMATOLOGICA, 2021, 106 (10) : 92 - 92
  • [24] Phase lb study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.
    Laubach, Jacob
    Tuchman, Sascha Alexander
    Rosenblatt, Jacalyn
    Redd, Robert
    Colson, Kathleen
    Motta, Ashley
    Fitzpatrick, Kathleen
    Weller, Edie
    Richardson, Paul G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Yasuo Mori
    Ilseung Choi
    Goichi Yoshimoto
    Tsuyoshi Muta
    Satoshi Yamasaki
    Kazuki Tanimoto
    Tomohiko Kamimura
    Hiromi Iwasaki
    Ryosuke Ogawa
    Koichi Akashi
    Toshihiro Miyamoto
    [J]. International Journal of Hematology, 2020, 111 : 673 - 680
  • [26] Phase I/II study of bortezomib, lenalidomide, and dexamethasone treatment for relapsed and refractory multiple myeloma
    Mori, Yasuo
    Choi, Ilseung
    Yoshimoto, Goichi
    Muta, Tsuyoshi
    Yamasaki, Satoshi
    Tanimoto, Kazuki
    Kamimura, Tomohiko
    Iwasaki, Hiromi
    Ogawa, Ryosuke
    Akashi, Koichi
    Miyamoto, Toshihiro
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (05) : 673 - 680
  • [27] Comparison of Time to Next Treatment or Death between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) and Bortezomib, Lenalidomide, and Dexamethasone (VRd) in Transplant Ineligible Patients with Multiple Myeloma
    Hansen, Doris K.
    Gautam, Santosh
    Lafeuille, Marie-Helene
    Rossi, Carmine
    Moore, Bronwyn
    Tardif-Samson, Anabelle
    Thompson-Leduc, Philippe
    Fu, Alex Z.
    Cortoos, Annelore
    Kaila, Shuchita
    Fonseca, Rafael
    [J]. BLOOD, 2023, 142
  • [28] LENALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN RELAPSE/ REFRACTORY MULTIPLE MYELOMA: A RETROSPECTIVE STUDY
    Firatli-Tuglular, T.
    Noyan-Atalay, F.
    Eser, A.
    Toptas, T.
    Pepedil, F.
    Kaygusuz-Atagunduz, I.
    Adiguzel, C.
    [J]. HAEMATOLOGICA, 2013, 98 : 614 - 615
  • [29] PHASE 3 RANDOMISED CONTROLLED STUDY OF DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CASTOR
    Palumbo, A.
    Chanan-Khan, A.
    Weisel, K.
    Nooka, A. K.
    Masszi, T.
    Beksac, M.
    Spicka, I.
    Hungria, V.
    Munder, M.
    Mateos, M. V.
    Mark, T.
    Qi, M.
    Schecter, J.
    Amin, H.
    Qin, X.
    Deraedt, W.
    Ahmadi, T.
    Spencer, A.
    Sonneveld, P.
    [J]. HAEMATOLOGICA, 2016, 101 : 340 - 341
  • [30] Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials
    Knauf, Wolfgang
    Aldaoud, Ali
    Losem, Christoph
    Mittermueller, Johann
    Neise, Michael
    Niemeier, Beate
    Harde, Johanna
    Trarbach, Tanja
    Potthoff, Karin
    [J]. LEUKEMIA RESEARCH, 2018, 68 : 90 - 97
12345